Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GSK Pays $1.4 Billion to Acquire Aiolos, which In-Licensed a Hengrui Asthma Candidate

publication date: Jan 11, 2024

GSK plans to acquire Aiolos Bio, a San Francisco-London startup, for $1 billion upfront and up to $400 million in regulatory milestones. Aiolos’ major asset is AIO-001, a long-acting mAb for asthma in Phase II trials. In August, Aiolos acquired global ex-China rights to the candidate from Jiangsu Hengrui Medicine (SHA: 600275) for $21.5 million upfront and over $1 billion in milestones plus royalties. AIO-001 targets the thymic stromal lymphopoietin (TSLP) cytokine, a driver of inflammation. Aiolos expects AIO-001 to require dosing only every six months. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital